Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
China’s Zhejiang Huahai Pharmaceutical has been named in U.S. litigation after its valsartan API was found to contain a suspected carcinogen.
Tasuku Honjo wins Nobel Prize for PD-1 research; Legend fires back at CAR-T data fabrication allegation; Takeda alumni demand more on Shire buyout.
It’s no secret that Takeda’s pending Shire megadeal has its critics, and some of them are now demanding behind-the-scenes info to justify the buy.
Nestlé, Unilever and Coca-Cola advanced to a second round of bidding for GSK's Indian consumer products business.
Dr. Reddy’s, which is trying to slim down in the face of regulatory issues, is selling its U.S. antibiotics plant to UAE-based Neopharma.
The EMA has taken action against China’s Zhejiang Huahai, whose valsartan API has been found to contain a suspected carcinogen.
Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.
U.S. medtech exports to China are targets in trade war; Alunbrig beats Xalkori in 1st-line lung cancer; FDA blasts Huahai for careless process changes.
China’s PharmaBlock Sciences says it has acquired a GMP-compliant manufacturing facility from Porton Pharma Solutions in Shangyu, China.